SAN DIEGO--(BUSINESS WIRE)--Halozyme Therapeutics, Inc. (Nasdaq:HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced the signing of an exclusive, worldwide, contract research collaboration agreement with BioAtla, LLC for the development of novel high throughput recombinant protein screening libraries directed against targets in oncology, aesthetic dermatology and inflammation. During the initial three year term of the research collaboration, Halozyme will receive exclusive worldwide commercial rights from BioAtla to conditionally active biologics (CABs) that arise from the agreement.
